The EC Sector Inquiry Into Pharmaceuticals: Quo Vadis, Commission?
This article will focus on the Commission’s antitrust enforcement agenda and examine two questions. First, why does the Reportâ€â€in spite of repeated disclaimers that it does not contain any finding of wrongdoingâ€â€create the impression that the pharmaceutical companies engage in many practices that are unlawful (infra Section 1)? Second, which antitrust policy principles should guide the Commission in any future enforcement action under Art. 81 and Art. 82 EC (infra Section 2)?
Year of publication: |
2009
|
---|---|
Authors: | Gyselen, Luc |
Published in: |
Antitrust Chronicle. - Competition Policy International. - Vol. 2.2009, 2
|
Publisher: |
Competition Policy International |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
The EC’s Sector Inquiry on Pharmaceuticals
Gyselen, Luc, (2008)
-
Article 86 [eighty-six] EEC: the monopoly power measurement issue revisited
Gyselen, Luc, (1986)
-
Gyselen, Luc, (1992)
- More ...